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Figure S1. Transcriptional regulation of proteasome genes in primary microglia with 
proteasome impairment.  (A) Quantitative RT-PCR analysis of Psmb8, Psmb9 and Psmb10 
mRNA levels encoding immunoproteasome catalytic subunits as well as Psma2 and Psmb6 
mRNA levels encoding standard proteasome catalytic subunits in primary microglia treated 
for 8 hours either with 200 nM of ONX-0914 or 50 nM of bortezomib. Mean ± SEM (n=3); 
*: P < 0.05, **: P < 0.01, ***: P < 0.001, unpaired two-sided t-test. (B) Immunoblotting 
depicting expression of NRF1 after bortezomib treatment. 
Figure S2. Proteasome activity in BV-2 cells treated with different doses of bortezomib. 
(A) Viability of BV-2 cells in response to different doses of bortezomib. Cells were treated 
with the indicated doses of BTZ for 6 hours and analyzed with the PreMix WST-1 Cell 
Proliferation Assay System. (B) Immunoblotting depicting expression of UPR drivers in 
response to indicated doses of bortezomib. (C) Presence of a spliced variant of XBP1s 
mRNA in response to bortezomib treatment was detected by PCR. XBP1u was observed as a 
204-bp band, and XBP1s was observed as a 178-bp band. Quantitative RT-PCR analysis of 
(D) Ifnβ1, (E) Cxcl-10, Ddit3/ CHOP, Eif2ak2/ PKR and (F) Il-6 mRNA levels. Mean ± SEM 
(n=3 technical replicates).  
Figure S3. Proteasome activity in BV-2 cells treated with 50 nM bortezomib. (A) 
Cytotoxicity test in response to 50 nM of bortezomib. Cells were treated for the indicated 
period of time with 50 nM of bortezomib and analyzed with the PreMix WST-1 Cell 
Proliferation Assay System. (B) An in-gel overlay experiment depicting chymotryptic-like 
activity of native proteasome complexes before and after the treatment with 50 nM of 
bortezomib. (C) Quantitative analysis of the chymotryptic-like activity of proteasomes 
treated with 50 nM of bortezomib.  Measurement was performed on native whole BV-2 cell 
lysates. (D) An in-gel analysis of proteasome activity after bortezomib treatment by use of 
the active site probe UbiQ-018 that fluorescently and covalently labels the β subunits of the 
proteasome in native whole cell lysates of BV-2. (E) Western blot analysis of poly-ubiquitin 
conjugates in BV-2 cells treated with bortezomib. (F) Quantification of ROS formation in 
cells treated with bortezomib. ROS was labelled with 2′-7′-dichlorofluorescin diacetate 
(DCFDA). Mean ± SEM (n=2) 
Figure S4. Transcriptional regulation of proteasome genes in BV-2 cells following 
treatment with bortezomib. (A) Quantitative RT-PCR analysis of immunoproteasome 
subunit Psmb8, Psmb9 and Psmb10 mRNA levels encoding immunoproteasome catalytic 
subunits as well as Psma2 and Psmb6 mRNA levels encoding standard proteasome catalytic 
subunits in BV-2 treated with 50 nM of bortezomib for indicated time. Mean ± SEM (n=5); 
*: P < 0.05, ***: P < 0.001, ****: P< 0.0001, unpaired two-sided t-test. (B) Immunoblotting 
depicting expression of NRF1 in BV-2 cells treated with bortezomib. (C) IL-6 expression 
levels in BV-2 upon bortezomib treatment measured by ELISA.  
Figure S5. Analysis of UPR and type I IFN response induction in BV-2 cells treated with 
ONX-0914. (A) Viability of BV-2 cells in response to different doses of ONX-0914. Cells 
were treated with the indicated doses of ONX-0914 for 6 hours and analyzed with the PreMix 
WST-1 Cell Proliferation Assay System. (B) Immunoblotting depicting expression of UPR 
drivers in response to indicated doses of ONX-0914. (D) Cytotoxicity test in response to 200 
nM of ONX-0914. Cells were treated with the indicated dose of ONX-0914 up to 24 hours 
and analyzed with the PreMix WST-1 Cell Proliferation Assay System. (D) Expression of 
standard- and immunoproteasome catalytic subunits and as well as UPR proteins visualized 
by western blotting. (E) Examination of the XBP1s mRNA splicing, visualized by PCR. (F) 
Immunoblotting depicting expression of type I IFN response drivers in BV-2 cells treated 
with ONX-0914.  
Figure S6. Analysis of UPR and type I IFN response induction in BV-2 cells treated with 
IFNβ1. BV-2 cells were treated with 100U of IFNβ1 up to 10 hours. Expression of (A) key 
drivers of type I IFN response, (B) standard- and immunoproteasome catalytic subunits and 
(C) CHOP and ATF6 proteins was visualized by immunoblotting.   
Figure S7. Analysis of effects of IFNα/β receptor blocker on the expression of 
interferon-stimulated genes in response to bortezomib treatment. (A) Immunoblotting 
depicting expression of type I IFN response drivers in BV-2 cells in response to a treatment 
with IFNAR blocking antibody (10 µg/ml) or the isotype IgG control. Quantitative RT-PCR 
analysis of (B) Ifnβ1, (C) Il-6, (D) Cxcl-10 and Eif2ak2/ PKR mRNA levels from whole 
RNA extracts of BV-2 cells. Mean ± SEM (n=3 technical replicates). (E) Immunoblotting 
depicting expression of main UPR proteins in BV-2 cells in response to the treatment with 
IFNAR blocking antibody (10 µg/ml) or the isotype IgG control.  
Figure S8. Induction of Interferon Stimulated Genes (ISGs) in BV-2 cells treated with 
IFNβ1. Quantitative RT-PCR analysis of ISGs mRNA levels in BV-2 cells treated with 100U 
of interferon β1 for indicated period of time. Mean ± SEM (n=3); *: P < 0.05, **: P < 0.01, 
unpaired two-sided t-test. 
Figure S9. Induction of Interferon Stimulated Genes (ISGs) in BV-2 cells following 
treatment with ONX-014. Quantitative RT-PCR analysis of ISGs mRNA levels in BV-2 
cells. Mean ± SEM. 
Figure S10. Proteasome subunits expression after the interference with the 
endonuclease activity of IRE1α. (A) Cytotoxicity test in response to proteasome and IRE1α 
inhibition with to 50 nM of bortezomib and 100 µM of 4µ8C inhibitor or the diluent, DMSO 
(0.1% v/v), respectively. Cell viability was analyzed with the PreMix WST-1 Cell 
Proliferation Assay System. (B) Immunoblotting depicting expression of proteasome subunits 
in BV-2 cells treated with 50 nM of bortezomib. Cells were pre-treated for 2 hours with 100 
µM of the 4µ8C inhibitor or with DMSO as a control. (C) Quantitative RT-PCR analysis of 
Ddit3/ CHOP and Eif2ak2/ PKR mRNA levels in BV-2 cells after the IRE1 inhibition. Mean 
± SEM (n=3). (D) Viability of THP-1 cells in response to different doses of bortezomib. Cells 
were treated for 6 hours and analyzed using the PreMix WST-1 Cell Proliferation Assay 
System. (E) Cytotoxicity test of THP-1 cells in response to 100 nM of bortezomib. Cells 
were treated with the indicated dose of BTZ up to 10 hours and analyzed using the PreMix 
WST-1 Cell Proliferation Assay System. (F) Immunoblotting depicting expression of type I 
IFN response drivers in THP1 cells treated with IRE1α inhibitor and 100 nM of bortezomib. 
Figure S11. Proteasome subunits expression after the interference with TBK1 kinase 
activity. (A) Cytotoxicity test in response to proteasome and TBK1 inhibition with to 50 nM 
of bortezomib and 100 µM of BX975 inhibitor or the diluent, DMSO (0.1% v/v), 
respectively. Cell viability was analyzed with the PreMix WST-1 Cell Proliferation Assay 
System. (B) Immunoblotting depicting expression of proteasome subunits in BV-2 cells 
treated with 50 nM of bortezomib. Cells were pre-treated for 1 hour with 1 µM of the TBK1 
inhibitor – BX795 or with DMSO as a control. (C) Quantitative RT-PCR analysis of Eif2ak2/ 
PKR mRNA level in BV-2 cells after TBK1 inhibition. Mean ± SEM (n=3).  
Figure S12. Induction of Interferon Stimulated Genes (ISGs) in CHOP deficient BV-2 
cells following bortezomib treatment. (A) Cytotoxicity test in response to proteasome 
inhibition and/ or CHOP knockdown. Cell viability was analyzed with the PreMix WST-1 
Cell Proliferation Assay System. Quantitative RT-PCR analysis of (B) Ifnβ1 mRNA level and 
(C) Cxcl10 as well as Eif2ak2/PKR mRNA levels in BV-2 cells. Mean ± SEM (n=3). 
 
 
Table S1. List of primers used for RT-qPCR analysis. 
Target gene Sequence 
RPLP0 forward 5´-CACACTCCATCATCAATGGG-3´ 
reverse 5´-TAGTCGAAGAGACCGAATCC-3´ 
 
IFNβ1 forward 5´-TGGGAGATGTCCTCAACTGC-3´ 
reverse 5´-TGCAACCACCACTCATTCTGA-3´ 
 
CXCL-10 forward 5´-GTGTTGAGATCATTGCCACG-3´ 
reverse 5´-AAGGAGCCCTTTTAGACCTT-3´ 
 
ISG-15 forward 5´-GAAGCAGACTCCTTAATTCCA-3´ 
reverse 5´-CTTTAGGTCCCAGGCCATTG-3´ 
 
EIF2AK2/ PKR forward 5´-ACAAATCGTGACCGGAGTGG-3´ 
reverse 5´-CAGGTCGGTCCTTGGGTTTC-3´ 
 
USP18 forward 5´-ATTGAAGAGGATAACAGTGCC-3´ 
reverse 5´-CGTGATCTGGTCCTTAGTCA-3´ 
 
PSMB8 forward 5´-TTGGTGGTGACCAGGAAAGG-3´ 
reverse 5´-GAGAGCCGAGTCCCATTGTC-3´ 
 
PSMB9 forward 5´-GAAGAAGTCCACACCGGGA-3´ 
reverse 5´-GGTTCCATATACCTGTCCCCC-3´ 
 
PSMB10 forward 5´-ACAAAAGCTGCGAGAAGAT-3´ 
reverse 5´-TGTGATGGCTTCCACCAA-3´ 
 
PSMA2 forward 5´-GTTCGTCCATTTGGTGTTTC-3´ 
reverse 5´-AGGGTTAAGATGGCTGTATGA-3´ 
 
PSMB6 forward 5´-CAGCTTGGTTTCCACAGTATT-3´ 
reverse 5´-TGTCTTACCATCATACCCCC-3´ 
 
CHOP forward 5´-GAACCTGAGGAGAGAGTGTT-3´ 
reverse 5´-TATAGGTGCCCCCAATTTCA-3´ 
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